

30 April 2025

BIOXYNE INVESTOR WEBINAR

Pharmaceutical and consumer health products Company, Bioxyne Limited (**ASX:BXN**) ("Bioxyne" or the "Company"), is pleased to invite shareholders and prospective investors to an online investor webinar.

The webinar will be held online via Teams on Thursday 1 May 2025, at 4:00pm AEST, where Managing Director, Sam Watson, will provide an update on the Company and engage in a live Q&A session.

Event: BXN Investor Webinar

Presenter: Managing Director – Mr Sam Watson

Time: Thursday, 1 May at 4:00pm AEST

Where: Teams Webinar, details to be provided upon registration

To register your interest for the webinar, please click the link below, or copy/paste the URL into your browser. After registering your interest, you will receive a confirmation email with information about joining the webinar on the day

Registration Link:

Attendees are able to submit questions for Q&A throughout the presentation to learn more about the Company.


https://events.teams.microsoft.com/event/79b1e1e9-6404-4c86-b0d3-2c3d5cf01788@6250ea43-b31c-4d3a-b60e-bba1d573338a

This announcement has been approved for release by the Board.

For further information contact:

Sam Watson
Managing Director
Bioxyne Limited
sam@breathelifesciences.com

Guy Robertson Chief Financial Officer Bioxyne Limited guy@bioxyne.com





Bi Exyne



Figure 3 – Bioxyne Activity Worldwide





About Bioxyne Ltd.

Bioxyne Limited (ASX:BXN) is an Australian-headquartered international consumer health and pharmaceutical company (incorporated in 2000) with a focus on clinically effective health and wellness products, psychotropic and investigational medicines.

About Breathe Life Sciences (BLS)

Breathe Life Sciences ("BLS") is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and licensed manufacturer, sponsor, importer and exporter of controlled substances (S3, S4, S8) in Australia.

BLS was founded in 2018 and has quickly expanded into a multi-national business focused on alternative therapeutics and investigational medicines. Our corporate head office is in Sydney, and our operations extend to licensed manufacturing, warehousing, import/export, sales and distribution centers in the Gold Coast (Australia), Nagoya (Japan), Manchester (UK), and Prague (Czechia).

Our business model is focused on manufacture of final dose form / finished products, sales and distribution in each of the territories we serve. We work with raw materials and API suppliers in 5 continents and are a market leader in manufacturing scope and quality.

The BLS logo is derived from a Japanese Maple Leaf, symbolising health, happiness and a long life well lived. While the Japanese Maple is not a medicinal plant, our company purpose is to redefine medicine by taking a holistic approach to healthcare for a healthier and happier tomorrow. Outside of Australia the BLS Group operates a health and wellness products and brands business focussed on naturally derived active nutraceuticals, wellness and lifestyle supplements and cannabidiol (CBD) based novel foods. It primarily operates in the UK, Europe and Japan, and engages in the following activities:

- a) Owner of Dr Watson® brand in the UK, Japan, Australia and New Zealand Dr Watson is an internationally recognized health, lifestyle, and prescription products brand. Dr Watson products consist of cannabis-based food supplements, lifestyle products, cosmetics, functional mushrooms and nootropics, and prescription medicines in Australia;
- b) Contract manufacture and wholesale of raw materials and cannabinoid extracts in Japan, UK and Europe;
- c) White label manufacture of third-party wellness and supplements brands in Japan, UK and Europe in companyowned facilities;
- d) Research and development for third party customers; and
- e) Direct sales via online and wholesale sales of BLS-owned consumer brands, such as Dr Watson®

United Kingdom: <u>drwatsoncbd.com</u>

■ Japan: nolcbn.com

Germany: <u>drwatsoncbd.de</u>

Corporate: https://bioxyne.com

Australia: https://bls.com.au; https://blsclinics.com.au

International: https://breathelifesciences.com

